Posts tagged as: SBFM back to homepage

Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News Sunshine Biopharma Shares Jump on Multi-Drug Resistant Breast Cancer Presentation News(0)

With the backdrop of news on Monday that Sunshine Biopharma, Inc. (OTCBB:SBFM) will be presenting new scientific data at the American Association for Cancer Research Meeting in Chicago, IL (to be held on March 31 – April 4, 2012), shares of the junior biotech surged a cool 100% to close Monday’s trading at 50 cents each. Read More

Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals(0)

It was only about a week ago that the U.S. Food and Drug Administration revoked the approval of Avastin® (bevacizumab) as a treatment for breast cancer.  This is not the end of the world for the Genentech, who was acquired by the Roche Holdings (OTCQX:RHHBY) for $46.8 billion in March of 2009, drug as it still retained its indications for colon, kidney, lung and brain cancer.  The revocation did, however, increase awareness for other breast cancer treatment candidates coming down the pipeline. Read More

Sunshine Biopharma Completes More In Vitro Cancer Research Sunshine Biopharma Completes More In Vitro Cancer Research(0)

Clearance of Sunshine Biopharma’s anti-cancer compound, Adva-27a, does not involve a toxic intermediate -
Sunshine Biopharma Inc. (OTCBB:SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed another study of the mechanism of clearance of its Adva-27a in human liver microsomes in vitro. In the present study, an analysis of the metabolic intermediates generated during the clearance process was performed.The study focused specifically on the generation of Podophyllotoxin, a potentially very toxic intermediate. In addition, the study was performed as a side-by-side experiment in which Adva-27a was compared to Etoposide, a commonly used Read More

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.